Omnicell, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing financial results for the three and nine months ended on that date.

Key Highlights

  • Quarterly net income: Omnicell reported net income of $11,044 thousand for the three months ended September 30, 2026, compared with $5,462 thousand in the same period of 2025, according to the filing.
  • Total revenues: The company reported total revenues of $307,851 thousand for Q3 2026, versus $310,631 thousand for Q3 2025.
  • Nine-month net income: For the nine months ended September 30, 2026, net income was $46,691 thousand, compared with $4,078 thousand for the same period of 2025.
  • Total assets: Total assets stood at $2,056,836 thousand as of September 30, 2026, up from $1,974,720 thousand as of December 31, 2025.
  • Cash position: Cash and cash equivalents were $314,856 thousand at September 30, 2026, compared with $196,520 thousand at December 31, 2025.
  • Diluted EPS: Diluted net income per share was $0.24 for Q3 2026 and $1.01 for the nine months ended September 30, 2026, per the filing.
  • Shares outstanding: As of the balance sheet date, 45,994 thousand shares of common stock were outstanding, with 12,806 thousand shares held as treasury stock.

Omnicell Reports Higher Income and Stronger Cash Position in Third Quarter of 2026

According to the Form 10-Q filed with the SEC, Omnicell, Inc. (NASDAQ:OMCL), a Delaware-incorporated company headquartered in Fort Worth, Texas, provides medication management and supply chain solutions to healthcare facilities. The company derives revenues from both product sales and service arrangements, with product revenues of $173,052 thousand and service revenues of $134,799 thousand reported for the third quarter of 2026.

The filing disclosed that gross profit for the three months ended September 30, 2026 was $137,826 thousand, compared with $134,503 thousand for the same quarter of 2025. Income from operations for Q3 2026 was $14,933 thousand, up from $8,244 thousand in Q3 2025. For the nine-month period, income from operations was $64,236 thousand, compared with $4,745 thousand in the first nine months of 2025, according to the filing.

On the balance sheet, total stockholders' equity increased to $1,317,255 thousand as of September 30, 2026, from $1,231,814 thousand as of December 31, 2025, the company disclosed. Retained earnings grew to $431,631 thousand from $384,940 thousand over the same period. The filing also noted convertible senior notes, net of $168,508 thousand among long-term liabilities, and goodwill of $737,125 thousand. Research and development expenses for the nine months ended September 30, 2026 were $64,170 thousand, while selling, general, and administrative expenses were $302,718 thousand, according to the filing.

What Was Disclosed

Omnicell filed its Form 10-Q for the quarter ended September 30, 2026, reporting higher net income, increased total assets, and a stronger cash balance compared with year-end 2025 and the prior-year quarter. Revenue mix included both product and service streams.